Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT05592275 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 3, 2023
- Completion date
- January 22, 2025
- Enrollment
- 332 (actual)
- Sites
- 137
Conditions
As the registry lists them; a condition with its own page is linked.
heart failure, heart failure with preserved ejection fraction